At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Mar 26, 2026 at 16:07 ET
Edwards Lifesciences Corp (EW) filed a DEFA14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing is a routine, management-sponsored solicitation requesting shareholder approval for the election of nine director nominees, an advisory vote on executive compensation, ratification of the independent auditor, and approval of an amended long-term stock incentive plan. The document includes a stockholder presentation highlighting the company's innovation strategy and board composition.
- The filing is a Definitive Additional Materials (DEFA14A) for the 2026 Annual Meeting.
- The Board is requesting shareholder approval for four proposals: election of nine directors, advisory vote on executive compensation, ratification of the independent auditor, and approval of an amended long-term stock incentive plan.
- The document includes a Spring 2026 Stockholder Presentation with forward-looking statements about the company's strategy and innovation.
- The board composition includes nine nominees with extensive experience in the medical technology industry.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access